首页> 美国卫生研究院文献>Molecular Pharmacology >Negative Gating Modulation by (R)-N-(Benzimidazol-2-yl)-1234-tetrahydro-1-naphthylamine (NS8593) Depends on Residues in the Inner Pore Vestibule: Pharmacological Evidence of Deep-Pore Gating of KCa2 Channels
【2h】

Negative Gating Modulation by (R)-N-(Benzimidazol-2-yl)-1234-tetrahydro-1-naphthylamine (NS8593) Depends on Residues in the Inner Pore Vestibule: Pharmacological Evidence of Deep-Pore Gating of KCa2 Channels

机译:(R)-N-(苯并咪唑-2-基)-1234-四氢-1-萘胺(NS8593)的负门控调制取决于内部孔前庭中的残留:深孔门控的药理学证据KCa2通道数

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Acting as a negative gating modulator, (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) shifts the apparent Ca2+-dependence of the small-conductance Ca2+-activated K+ channels KCa2.1–2.3 to higher Ca2+ concentrations. Similar to the positive KCa channel-gating modulators 1-ethyl-2-benzimidazolinone (1-EBIO) and cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methylpyrimidin-4-yl]-amine (CyPPA), the binding site for NS8593 has been assumed to be located in the C-terminal region, in which these channels interact with their Ca2+ sensor calmodulin. However, by using a progressive chimeric approach, we were able to localize the site-of-action of NS8593 to the KCa2 pore. For example, when we transferred the C terminus from the NS8593-insensitive intermediate-conductance KCa3.1 channel to KCa2.3, the chimeric channel remained as sensitive to NS8593 as wild-type KCa2.3. In contrast, when we transferred the KCa2.3 pore to KCa3.1, the channel became sensitive to NS8593. Using site-directed mutagenesis, we subsequently identified two specific residues in the inner vestibule of KCa2.3 (Ser507 and Ala532) that determined the effect of NS8593. Mutation of these residues to the corresponding residues in KCa3.1 (Thr250 and Val275) made KCa2.3 insensitive to NS8593, whereas introduction of serine and alanine into KCa3.1 was sufficient to render this channel highly sensitive to NS8593. It is noteworthy that the same two residue positions have been found previously to mediate sensitivity of KCa3.1 to clotrimazole and 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34). The location of Ser507 in the pore-loop near the selectivity filter and Ala532 in an adjacent position in S6 are within the region predicted to contain the KCa2 channel gate. Hence, we propose that NS8593-mediated gating modulation occurs via interaction with gating structures at a position deep within the inner pore vestibule.
机译:作为负门控调节剂,(R)-N-(苯并咪唑-2-基)-1,2,3,4-四氢-1-萘胺(NS8593)改变表观Ca 2 + Ca 2 + 激活的K + 通道KCa2.1–2.3对高Ca 2 + 浓度的依赖性。类似于正KCa通道门控调节剂1-乙基-2-苯并咪唑啉酮(1-EBIO)和环己基-[2-(3,5-二甲基-吡唑-1-基)-6-甲基嘧啶-4-基]-胺(CyPPA),NS8593的结合位点被认为位于C端区域,在这些区域中,这些通道与其Ca 2 + 传感器钙调蛋白相互作用。但是,通过使用渐进式嵌合方法,我们能够将NS8593的作用位点定位在KCa2孔中。例如,当我们将C末端从NS8593不敏感的中等电导KCa3.1通道转移到KCa2.3时,嵌合通道对NS8593的敏感性仍然与野生型KCa2.3相同。相反,当我们将KCa2.3孔转移到KCa3.1时,通道对NS8593变得敏感。使用定点诱变,我们随后在KCa2.3的内部前庭中确定了两个特定的残基(Ser507和Ala532),这些残基决定了NS8593的作用。这些残基突变为KCa3.1中相应的残基(Thr250和Val275)使KCa2.3对NS8593不敏感,而将丝氨酸和丙氨酸引入KCa3.1足以使该通道对NS8593高度敏感。值得注意的是,先前已经发现相同的两个残基位置介导了KCa3.1对克霉唑和1-[((2-氯苯基)二苯基甲基] -1H-吡唑(TRAM-34)的敏感性。 Ser507在选择性过滤器附近的孔环中的位置以及Ala532在S6中的相邻位置中的位置在预计包含KCa2通道门的区域内。因此,我们提出NS8593介导的门控调节是通过与内孔前庭深处的门控结构相互作用而发生的。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号